SNAP-8 – Product Description

The Advanced Octapeptide for SNARE Complex Research and Topical Formulation Studies

SNAP-8 10 mg: SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide designed as an advanced analog of the N-terminal domain of the SNAP-25 protein, a core component of the SNARE complex essential for neurotransmitter release . Building upon the legacy of its predecessor, Argireline (Acetyl Hexapeptide-3), SNAP-8 incorporates a two-amino-acid C-terminal extension that enhances its structural mimicry and functional activity, making it a subject of interest in cellular communication, vesicle fusion dynamics, and topical formulation research .

Table of Contents

1. What is SNAP-8?

2. Mechanism of Action

3. Key Research Findings

4. Product Specifications

5. Dosing and Administration

6. Safety Profile

7. Frequently Asked Questions (FAQs)

8. References

What is SNAP-8?

SNAP-8, also known as Acetyl Octapeptide-3, is a synthetic peptide with the amino acid sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ . It is an engineered analogue of the N-terminal domain of SNAP-25 (Synaptosomal-Associated Protein of 25 kDa), a protein integral to the SNARE complex that mediates synaptic vesicle fusion and neurotransmitter release .

Mechanism of Action

SNAP-8 functions primarily through competitive inhibition of the SNARE complex assembly .

The peptide’s N-terminal acetylation and C-terminal amidation enhance its stability and structural mimicry of the native protein . Binding affinity studies report a dissociation constant (Kd) of approximately 0.8 μM for SNAP-8 binding to syntaxin . Functional assays demonstrate that SNAP-8 at 1.5 mM inhibits 43% of glutamate release in neuronal model systems, a validated proxy for acetylcholine release .

Key Research Findings

Head-to-Head Efficacy vs. Argireline

The primary research differentiator for SNAP-8 is its demonstrated performance advantage over Argireline:

In a manufacturer-conducted comparative clinical study, a 10% SNAP-8 solution reduced wrinkle depth by 34.98% over 28 days, compared to 27.05% for Argireline under identical conditions . This absolute difference of 7.93 percentage points represents a relative improvement of approximately 29% .

SNARE Complex Inhibition

Research demonstrates that SNAP-8 effectively competes with native SNAP-25 for a position in the SNARE complex . In vitro assays measuring SNARE complex formation showed that SNAP-8 impedes complex assembly in a dose-dependent manner, destabilizing the vesicle fusion machinery .

Glutamate Release Modulation

Functional assays in neuronal cell cultures confirmed that SNAP-8 inhibits glutamate release in a dose-dependent fashion, with 43% inhibition observed at a 1.5 mM concentration . This mechanism is central to its role in modulating synaptic vesicle exocytosis.

Structural Biology and Computational Modeling

SNAP-8’s modest size makes it a valuable tool for computational biology. It is amenable to molecular dynamics simulations exploring conformational flexibility, residue-specific interactions, and theoretical binding affinities . These models help refine understanding of which structural features of the SNAP-25 N-terminal domain are most responsible for SNARE component interactions .

Product Specifications

Dosing and Administration

SNAP-8 is a research peptide with applications in both in vitro assays and topical formulation studies.

Reconstitution and Storage

• Reconstitution: Dissolve lyophilized powder in sterile water or appropriate aqueous buffer. Solubility exceeds 2 mg/mL in water.

• Storage: Powder should be stored at -20°C, protected from moisture and light.

• Stability: SNAP-8 is reported to be more stable than Argireline in formulation conditions .

Safety Profile

SNAP-8 is generally considered well-tolerated in research and topical formulation studies. Comparative analyses note that SNAP-8 has lower potency and toxicity than botulinum toxin, with no serious adverse effects reported in clinical studies .

Known Considerations

• Cutaneous Absorption: As with other peptides, SNAP-8’s molecular weight (~1075 Da) and hydrophilic nature may limit transdermal permeability, a factor to consider in formulation research .

• In Vitro Safety: No significant toxicity reported in cell-based assays at research concentrations .

Important Safety Considerations

• Not FDA-Approved: SNAP-8 is not FDA-approved for human therapeutic use. It is a research compound strictly intended for laboratory and in vitro experimentation .

• Research Context: The primary evidence base is from in vitro studies and manufacturer-conducted human trials, with independent replication of large clinical findings limited .

Frequently Asked Questions (FAQs)

1. What is SNAP-8 used for in research?

SNAP-8 is used to study SNARE complex biology, synaptic vesicle fusion mechanisms, neurotransmitter release pathways, and as a reference material for analytical methods such as HPLC and mass spectrometry . It is also studied in topical formulation research for its interaction with neurotransmitter-associated pathways and skin appearance endpoints .

2. How does SNAP-8 differ from Argireline?

SNAP-8 is an extended analogue of Argireline (Acetyl Hexapeptide-3), incorporating two additional C-terminal amino acids (Ala-Asp) followed by amidation . This extension enhances structural mimicry of the SNAP-25 N-terminal domain, resulting in approximately 30% greater bioactivity and superior SNARE complex binding .

3. What is the mechanism of action?

SNAP-8 competes with native SNAP-25 for binding sites within the SNARE complex, destabilizing complex formation and attenuating neurotransmitter release at the neuromuscular junction . This reversible interaction modulates muscle contraction without causing permanent paralysis .

4. What is the molecular structure of SNAP-8?

SNAP-8 is an octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ . It features N-terminal acetylation and C-terminal amidation modifications that enhance stability . Its molecular weight is approximately 1073–1075 Da .

5. Is SNAP-8 FDA-approved?

No. SNAP-8 is not FDA-approved for human therapeutic or cosmetic use. It is strictly intended for laboratory and research purposes only .

6. What are the storage requirements?

Lyophilized SNAP-8 powder should be stored at -20°C, protected from moisture and light. Reconstituted solutions should be aliquoted to avoid repeated freeze-thaw cycles.

7. Is SNAP-8 natural?

Cosmetic-grade SNAP-8 peptide solutions are marketed with a natural origin content of up to 99.49% according to ISO 16128 , but this refers to the solution matrix rather than the synthetic peptide itself.